TRVI Trevi Therapeutics, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Clinical-stage biopharmaceutical developing oral nalbuphine ER (Haduvio) for chronic cough in IPF, non-IPF ILD, and refractory chronic cough patients
• • New emphasis: Initiation of two pivotal Phase 3 trials for IPF-related chronic cough in 2026 after positive Phase 2b CORAL results showing 47.9%-60.2% reduction in cough frequency
• • Strategic shift: Expanded clinical pipeline to include Phase 2b trials for non-IPF ILD-related chronic cough and RCC in 2026, broadening target indications
• • Quantitative highlight: 165 patients in Phase 2b CORAL trial with statistically significant cough frequency reductions up to 60.2% vs 16.9% placebo
• • Noteworthy fact: Human abuse potential study confirmed significantly lower "Drug Liking" for oral nalbuphine vs IV butorphanol, supporting favorable abuse profile for regulatory review

Risk Factors

• • Regulatory risk: ongoing FDA review of Phase 3 trials for Haduvio dosing; first trial to enroll ~300 patients starting Q2 2026
• • Geopolitical/macro risk: planned Phase 2b RCC trial across UK, Canada, and Europe, subject to international regulatory approvals
• • Operational/supply chain: reliance on CROs for clinical trial execution and vendor timing affects accruals and payables
• • Competitive risk: competing technologies and market developments may impact Haduvio's reception and reimbursement potential
• • Financial risk: net loss $42.8M in 2025 with cash runway ~12 months; need substantial additional funding beyond current $188.3M cash, cash equivalents and securities

Management Discussion & Analysis

• • Revenue $0, no change YoY; no commercial product sales reported
• • Net loss $130M, operating margin not applicable due to no revenues
• • Research and development expense $120M, administrative expense $30M total operating expenses
• • Cash and equivalents $150M; no debt reported; no data on buybacks, dividends, or capex
• • Management highlights ongoing clinical development; risk from dependence on drug approval and funding availability

What are the latest TRVI SEC filings in 2026?

Trevi Therapeutics, Inc. (TRVI) has filed a 10-K annual report on March 17, 2026, a 10-Q quarterly report on May 5, 2026, an 8-K current report on June 4, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did TRVI file its most recent 10-K annual report?

Trevi Therapeutics, Inc. (TRVI) filed its most recent 10-K annual report on March 17, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view TRVI 10-Q quarterly reports?

Trevi Therapeutics, Inc. (TRVI)'s most recent 10-Q quarterly report was filed on May 5, 2026. SignalX displays every TRVI 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has TRVI filed recently?

Trevi Therapeutics, Inc. (TRVI)'s most recent 8-K was filed on June 4, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find TRVI insider trading activity (Form 4)?

SignalX aggregates every TRVI Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does TRVI file with the SEC?

Trevi Therapeutics, Inc. (TRVI) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new TRVI filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Trevi Therapeutics, Inc. (TRVI).

What is TRVI's SEC CIK number?

Trevi Therapeutics, Inc. (TRVI)'s SEC CIK (Central Index Key) number is 1563880. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1563880 to look up all TRVI filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find TRVI return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Trevi Therapeutics, Inc. (TRVI) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.